17)
Andrews J. et al.：J. Antimicrob. Chemother.，51：727，2003.［GEN-00102］

18)
Hayakawa H. et al.：Drug Metab. Dispos.，31：1409，2003.［GEN-00109］

19)
高畑正裕ほか：日本化学療法学会雑誌，55(S-1)：1，2007.［GEN-00217］

2．文献請求先・製品情報お問い合わせ先

主要文献に記載の社内資料につきましても下記にご請求下さい。

*アステラス製薬株式会社　メディカルインフォメーションセンター

〒103-8411　東京都中央区日本橋本町2丁目5番1号

0120-189-371

**大正富山医薬品株式会社　メディカルインフォメーションセンター

〒170-8635　東京都豊島区高田3－25－1

電話　0120-591-818

製造販売業者等の氏名又は名称及び住所

発売
アステラス製薬株式会社

東京都中央区日本橋本町2丁目5番1号

販売提携
大正富山医薬品株式会社

東京都豊島区高田3-25-1

製造販売
富山化学工業株式会社

東京都新宿区西新宿3-2-5
Quinolone oral synthetic antibacterial agent "Geninac (R) tablet 200 mg" announced on domestic new release on October 5
Taisho Toyama Pharmaceutical Co., Ltd. (Head office: Tokyo, President: Masaki Nogi Mori, hereinafter "Astellas Pharma") and Taisho Toyama Pharmaceuticals Co., Ltd. (Head office: Tokyo, President: Akira Ohira, hereinafter "Taisho Toyama Pharmaceuticals") and Toyama Chemical Industry Co., (Generic name: galenoxacin mesylate hydrate, development number: T (head name: Masashi Sugata, President: Masashi Sugata, hereinafter "Toyama Chemistry") is a quinolone oral synthetic antibacterial agent " -3811) will be released in Japan on October 5th.
This drug is a new type of quinolone synthetic antibacterial agent created by Toyama Chemistry and has excellent antibacterial activity against the respiratory and otorhinolaryngology infectious disease infectious diseases including resistant bacteria such as multidrug resistant pneumococci It is a medicine that can expect excellent clinical effect once a day administration by good oral absorbability and tissue migration. In addition, since this drug was the first synthetic antimicrobial agent to express penicillin-resistant pneumococci on the type of indication, the addition of usefulness was recognized compared to the drug price of existing drugs. In Japan, Toyama Chemical and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Akira Uehara) jointly developed respiratory infections and otorhinolary infections as target indications.
In March 2006, Toyama Chemical and Astellas Pharma have signed basic license agreement on sales and co-development in Japan, Toyama Chemical manufactures the same, Astellas Pharma distributes and sells it We will conduct sales promotion activities (co · promotion) in collaboration with Taisho Toyama Medicine.
The outline of "Geninac (R) tablet 200 mg" is as follows.
Manufacturing marketing approval acquisition date July 31, 2007
Product name Geninac (R) tablet 200 mg (English name: Geninax (R))
Generic name galenoxacin mesylate hydrate (English name: Garenoxacin Mesilate Hydrate)
Classification synthetic antibacterial agent
Indication / effect <Adaptive fungal species>
Escherichia coli, Klebsiella, Enterobacter, Haemophilus influenzae, Legionella pneumophila, Chlamydia pneumoniae (Staphylococcus aureus), which are sensitive to galenoxacin, Streptococcus, Streptococcus pneumoniae (including penicillin-resistant pneumococci), Moraxella (Blanhamera) Chlamydia pneumoniae), pneumonia mycoplasma (Mycoplasma pneumoniae)
<Indication>
Sore throat · laryngitis, tonsillitis (including amygdalis, amygdala abscess